Table 1.
Patient, tumour and treatment characteristics.
| PORTEC-3 | MST | Total | |
|---|---|---|---|
| n = 411 (100.0%) | n = 237 (100.0%) | n = 648 (100.0%) | |
| Age | |||
| Mean (range) | 61.2 (26.7–80.5) | 68.5 (25.0–92.0) | 63.8 (25.0–92.0) |
| Histotype and grade | |||
| Low-grade endometrioid | 162 (39.4) | 92 (38.8) | 254 (39.2) |
| High-grade endometrioid | 113 (27.5) | 66 (27.8) | 179 (27.6) |
| Serous | 65 (15.8) | 23 (9.7) | 88 (13.6) |
| Clear cell | 40 (9.7) | 13 (5.5) | 53 (8.2) |
| Mixed | 23 (5.6) | 8 (3.4) | 31 (4.8) |
| Carcinosarcoma | 0 (0.0) | 24 (10.1) | 24 (3.7) |
| Un-/dedifferentiated | 7 (1.7) | 9 (3.8) | 16 (2.5) |
| Other | 1 (0.2) | 2 (0.8) | 3 (0.5) |
| Stage | |||
| IA | 54 (13.1) | 22 (9.3) | 76 (11.7) |
| IB | 73 (17.8) | 58 (24.5) | 131 (20.2) |
| II | 106 (25.8) | 75 (31.6) | 181 (27.9) |
| III | 178 (43.3) | 82 (34.6) | 260 (40.1) |
| LVSI | |||
| Absent | 155 (37.7) | 186 (78.5) | 341 (52.6) |
| Present | 256 (62.3) | 51 (21.5) | 307 (47.4) |
| Received treatment | |||
| EBRT | 204 (49.6) | 199 (85.0) | 403 (62.5) |
| EBRT + CTa | 207 (50.4) | 16 (6.8) | 223 (34.6) |
| VBT | 0 (0.0) | 19 (8.1) | 19 (2.9) |
| Molecular subgroup | |||
| POLEmut | 52 (12.7) | 15 (6.3) | 67 (10.3) |
| MMRd | 138 (33.6) | 68 (28.7) | 206 (31.8) |
| p53abn | 99 (24.1) | 68 (28.7) | 167 (25.8) |
| NSMP | 122 (29.7) | 86 (36.3) | 208 (32.1) |
| ER IHC | |||
| Negative (<10%) | 92 (24.2) | 77 (32.5) | 169 (27.4) |
| Positive (≥10%) | 288 (75.8) | 160 (67.5) | 448 (72.6) |
| PR IHC | |||
| Negative (<10%) | 165 (41.6) | 112 (47.9) | 277 (43.9) |
| Positive (≥10%) | 232 (58.4) | 122 (52.1) | 354 (56.1) |
| L1CAM IHC | |||
| Negative (<10%) | 293 (72.2) | 171 (72.2) | 464 (72.2) |
| Positive (≥10%) | 113 (27.8) | 66 (27.8) | 179 (27.8) |
| CTNNB1 exon 3 | |||
| No mutation | 290 (83.8) | 176 (89.3) | 466 (85.8) |
| Mutation | 56 (16.2) | 21 (10.7) | 77 (14.2) |
LVSI lymphovascular space invasion, EBRT external beam radiotherapy, CT chemotherapy, VBT vaginal brachytherapy, POLEmut POLE-ultra-mutated, MMRd mismatch repair-deficient, p53abn p53-abnormal, NSMP no specific molecular profile.
aTwo patients received VBT + CT.